Stay updated with breaking news from Xiaobin Wu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have been given an average recommendation of “Buy” by the eight ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The […]
Equities research analysts expect BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) to report sales of $332.26 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for BeiGene’s earnings, with the highest sales estimate coming in at $347.62 million and the lowest estimate coming in at $316.90 million. BeiGene reported […]
BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for
Tislelizumab is now approved for eight indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative